Waldencast Obagi shares interim ALOHA trial data for Saypha MagIQ dermal filler

Waldencast plc Class A

Waldencast plc Class A

WALD

0.00
  • Waldencast unit Obagi Medical presented new clinical and real-world data at Music City SCALE meeting running May 13-17 in Nashville.
  • 12-week open-label study of NU-GEN Cellular Renewal Serum showed visible improvements across multiple signs of skin aging, supporting positioning of product as anti-aging regimen without disclosing detailed measurements.
  • Interim readout from ALOHA real-world program for Obagi Saypha MagIQ hyaluronic acid filler indicated broad injector acceptance as complement to existing filler portfolios, supporting commercial rollout strategy in aesthetic practices.
  • Program data also signaled cross-selling potential, with meaningful share of filler patients evaluating Obagi skincare alongside injectables.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Waldencast plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605150813PRIMZONEFULLFEED9720674) on May 15, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.